• Docetaxel and paclitaxel are well established treatments for metastatic breast cancer (MBC)
Introduction
• To compare NP and NP-related outcomes between patients with early-stage BC treated with adjuvant doxetaxel-or paclitaxel-based regimens in a community practice
Objective

Data Source
• Electronic medical records (EMR) from the Georgia Cancer Specialist Database (GCSD) from 2003 -2008 supplemented by chart review
• EMR data from GCSD include patient demographic characteristics, disease information, CT protocols, hospitalization services, outpatient services, infusion drug claims (including CT and non-CT-related), outpatient prescriptions, laboratory results, and insurance information
• Chart review was conducted to collect information regarding surgery, radiation therapy, disease recurrence, and neuropathy for early-stage BC patients treated with CT
Study Sample
• Patients from GCSD who met the following criteria ➢ Stage I-III BC (without other cancer-types) ➢ Received adjuvant treatment with docetaxel-or paclitaxel-based CT ➢ Patients were followed from CT initiation to the earliest of death, loss to follow-up, or switch to other regimens
Outcomes and Covariates
• Study outcomes ➢ Risk of severe NP (common toxicity criteria grade 3 or 4) ➢ Risk of using NP-related medications (NPMs) ➢ Risk of CT being interrupted 
Statistical Analysis
• Descriptive analyses ➢ Chi-square tests for categorical variables (ie, CCI post diagnosis, smoke status at diagnosis, race, diagnosis stage, surgery post diagnosis, and radiation post diagnosis)
➢ Two-sample t-tests for continuous variables (ie, age at diagnosis and BMI at diagnosis) ➢ Log-rank tests for Kaplan-Meier survival curves
• Multivariate analyses ➢ Multivariate Cox proportional hazard model was used for time to severe NP and time to NPMs ➢ Multivariate logistic regression model was used for the risk of CT being interrupted
• Subgroup analyses ➢ Secondary subsample: patients treated with most dominant CT schedule from each group ➢ Descriptive and multivariate analyses were conducted as for the overall sample
Descriptive Statistics
• Patient characteristics shown in • Within 6 months, the rates of NPM use were 7.6% and 28.1% for docetaxel-treated and paclitaxel-treated patients, respectively (p<0.0001) (Figure 3) • CT was more likely to be affected for patients in the paclitaxel group versus the docetaxel group (7.1% vs. 1.5%; p<0.001) • Using data from a community oncology practice, this study found that adjuvant paclitaxel-containing regimens were associated with higher risks for NP-related outcomes (ie, severe NP, use of NPM, and CT being interrupted due to NP), compared with docetaxel-containing regimens in patients with early-stage BC
Risk of NPM (%)
• The results were robust after adjusting for available potential clinical and demographic confounders
• These findings are consistent with those from clinical trials comparing docetaxel-and paclitaxel-based regimens in MBC [2] [3] [4] [5] • Since the data were from 1 community practice, the results should be interpreted with caution. Additional studies from other community settings are needed to confirm these findings
Discussion
Subgroup Analysis
• Results from the subsample (N= 594) were similar to the overall sample ➢ Within 6 months, the rate of severe NP was 1% for patients treated with docetaxel Q3W compared with 6.9% for paclitaxel-treated patients Q2W (p<0.0001); similarly, NPM was 5.8% versus 24.8% (p<0.0001)
➢ Multivariate analysis results showed that paclitaxel Q2W was associated with increased risks for severe NP (HR= 28.4; p=0.0017); NPM use (HR= 4.26; p<0.0001); and CT interruption (odds ratio = 14.8; p=0.0002)
